If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Senior Technical Advisor for Science and Technology, Office of Population and Reproductive Health, Bureau for Global Health, United States Agency for International Development, Washington, DC, USA 20523–3600
Sayana® Press (SP) is a 104-mg single dose of medroxyprogesterone acetate (MPA) in
0.65-mL volume, sterilely packaged in the Uniject device. Uniject is a pre-filled,
non-reusable blister injection system consisting of a bubble reservoir with an integral,
ultra-thin needle. (For a picture of SP, see below and Fig 1 in both accompanying papers by Keith [
].) In this issue of Contraception, a group of papers address the acceptability of Sayana® Press (also known as Depo
subQ Provera 104™ in Uniject) and other research related to this new product. These
papers also identify some of the challenges to SP reaching its full potential as a
new contraceptive option in low-resource settings, especially in sub-Saharan Africa
and South and Central Asia, where unmet need for family planning is the greatest.
SP could be a “game changer,” in part, due to its potential for in-home or self-injection.
In addition, given the safety and ease of subcutaneous injections with SP, some Ministries
of Health may be more likely to enact policy change to permit community health workers
(CHWs) and other community-level workers (e.g., drug shop keepers) to provide injectables
in countries that currently only permit higher level providers to do so. At a reasonable
price, this new product has the potential to expand contraceptive choice and use in
underserved communities that otherwise might not have access to injectable contraceptives.
Members of the Rakai Health Sciences Program Sayana Press Study Team. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
